ArticleFrontiers in oncology2025
The clinical application potential assessment of the Deepseek-R1 large language model in lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative Evaluation of ChatGPT, DeepSeek, and Physician-Generated Acupuncture Treatment Protocols Across Chinese and English Language Settings: Cross-Sectional Evaluation Study.JMIR formative research · 2026Article
- Evaluating Large Reasoning Models Versus Human Multidisciplinary Teams in Lung Cancer Decision-Making: Real-World Study.Journal of medical Internet research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluates the clinical potential of the large language model Deepseek-R1 in the diagnosis and treatment of lung cancer, with a specific focus on its ability to assist junior oncologists. The research systematically assesses the model's performance in terms of diagnostic accuracy, consistency of treatment recommendations, and reliability in clinical decision-making. Methods: A total of 320 patients newly diagnosed with lung cancer were included in this retrospective study. Twenty-six structured clinical questions were designed based on international diagnostic and treatment guidelines. These questions addressed three key domains: basic medical knowledge, complex clinical decision-making, and ethical judgment. All patient data were anonymized before being entered into the Deepseek-R1 model. The model's responses, along with those generated by five junior oncologists with no more than three years of clinical experience, were independently assessed by senior oncologists with over ten years of experience. A double-blind evaluation protocol was implemented to reduce potential assessment bias. Inter-rater agreement was quantified using Cohen's Kappa coefficient. Results: In the categories of basic knowledge, advanced clinical decisions, and ethical questions, Deepseek-R1 achieved average accuracy rates of 92.3%, 87.5%, and 85.1%, respectively. These rates were significantly higher than those of junior oncologists, whose accuracy rates were 80.4%, 72.8%, and 70.2%, respectively (P < 0.05). In a sample of 256 cases evaluated formally, Deepseek-R1's overall diagnostic accuracy was 94.6%, compared to 78.9% for junior oncologists (P < 0.05). In a longitudinal assessment of 40 cases with disease progression, the model demonstrated high consistency in updating its recommendations. Logical errors were more frequent among junior oncologists, while ethical risks appeared more commonly in the model-generated responses (44% vs. 21.9%). Conclusion: Deepseek-R1 significantly outperformed junior oncologists in terms of diagnostic accuracy and treatment decision-making, particularly in complex and dynamic clinical situations. While limitations remain in its ethical reasoning, the model holds substantial potential for supporting junior physicians, contributing to multidisciplinary discussions, and optimizing treatment pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.